Researchers warn about false and misleading ketamine ads

Abstract

In a research letter published Nov. 7 in JAMA Network Open, Matthew A. Crane, a student at Johns Hopkins School of Medicine, and colleagues discuss direct‐to‐consumer ketamine advertising with false or misleading claims. The advertisers had at least one clinic and a website. Claims were called false or misleading “if they contradicted evidence accumulated through a multidisciplinary review or contradicted FDA statements,” according to the letter. They conducted the research in order to brief Maryland regulators, the letter authors wrote.